PLIAGLIS

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Hong Kong SAR China, Ireland, Poland, Singapore, Spain.

Active ingredients

The drug PLIAGLIS contains a combination of these active pharmaceutical ingredients (APIs):

1	Lidocaine UNII 98PI200987 - LIDOCAINE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine
2	Tetracaine UNII 0619F35CGV - TETRACAINE
	Tetracaine is a local anaesthetic and is believed to act by blocking nerve conduction mainly by inhibiting sodium ion flux across the axon membrane.
	Read more about Tetracaine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BB52	Lidocaine, combinations	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	510114010005605
CA	Health Products and Food Branch	02398028
ES	Centro de información online de medicamentos de la AEMPS	76730
HK	Department of Health Drug Office	63840
PL	Rejestru Produktów Leczniczych	100283348
SG	Health Sciences Authority	14793P
US	FDA, National Drug Code	51672-5305, 73575-009, 73575-010